Serous and mucinous borderline tumors of the ovary: A clinicopathologic and DNA-ploidy study of 102 cases

International Journal of Gynecological Cancer

Volumn 6, Issue 4, 1996, Pages 302-308

  Kuoppala, T ^a   Heinola, M ^a   Aine, R ^a   Isola, J ^a   Heinonen, P K ^a,b  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

borderline; CA125; flow cytometry; mucinous; ovarian tumors; serous

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DNA; EPIRUBICIN; MELPHALAN; RECOMBINANT ALPHA2B INTERFERON; TEGAFUR;

ABDOMINAL HYSTERECTOMY; ADOLESCENT; ADULT; AGED; ANEUPLOIDY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CONSERVATIVE TREATMENT; CYSTADENOMA; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY TUMOR; PERITONEUM PSEUDOMYXOMA; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; REGIONAL PERFUSION; SALPINGOOOPHORECTOMY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0030018395     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.1996.06040302.x     Document Type: Article

References (28)

1. Taylor HC. Malignant and semimalignant tumors of the ovary. Surg Cynecol Obstet 1929; 48: 204-30.
2. Fox H. The concept of borderline malignancy in ovarian tumors: a reappraisal. Curr Top Pathol 1989; 78: 111-34.
3. Botswick DG, Tazelaar HD, Ballon SC, Hendrickson MR, Kempson RL. Ovarian epithelial tumors of borderline malignancy. Cancer 1986; 58: 2052-65.
4. Kaern J, Tropé CG, Abeler VM. A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathological features and treatment modalities. Cancer 1993; 71: 1810-20.
5. Padberg P-C, Arps H, Franke U, et al. DNA cytophotometry and prognosis in ovarian tumors of borderline malignancy. A clinicopathological study of 80 cases. Cancer 1992; 69: 2510-4.
6. Kaern J, Tropé CG, Kristensen GB, Abeler VM, Pettersen EO. DNA ploidy; the most important prognostic factor in patients with borderline tumors of the ovary. Int J Gynecol Cancer 1993; 3: 349-58.
7. Makar APh, Kaern J, Kristensen GB, Vergote I, Bormer OP, Tropé CG. Evaluation of serum CA125 level as a tumor marker in borderline tumors of the ovary. Int J Gynecol Cancer 1993; 3: 299-303.
8. Kallioniemi O-P. Comparison of fresh and paraffin-embedded tissue as starting material for DNA flow cytometry and evaluation of intratumor heterogeneity. Cytometry 1988; 9: 164-9.
9. Kallioniemi O-P, Visakorpi T, Holli K, Heikkinen A, Isola J, Koivula T. Improved prognostic impact of S-phase values from paraffin-embedded breast and prostate carcinomas after correcting for nuclear slicing. Cytometry 1991; 12: 413-21.
10. Dean PN, Jett JH. Mathematical analysis of DNA distributions derived from microfluorometry. J Cell Biol 1974; 60: 523-7.
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc, 1958; 53: 457-81.
12. Nakashima N, Nagasaka T, Oiwa N, Nara Y, Fukata S, Fukatsu T, Takeuchi J. Ovarian epithelial tumors of borderline malignancy in Japan. Gynecol Oncol 1990; 38: 90-8.
13. Kliman L, Rome RM, Fortune DW. Low malignant potential tumors of the ovary: a study of 76 cases. Obstet Gynecol. 1986; 68: 338-44.
14. Nation JG, Krepart GV. Ovarian carcinoma of low malignant potential: staging and treatment. Am J Obstet Gynecol 1986; 154: 290-3.
15. Snider DD, Stuart GCE, Nation JG, Robertson DI. Evaluation of surgical staging in stage I low malignant potential ovarian tumors. Gynecol Oncol 1991; 40: 129-32.
16. Hopkins MP, Kumar NB, Morley GW. An assessment of pathologic features and treatment modalities in ovarian tumors of low malignant potential. Obstet Gynecol 1987; 70: 923-9.
17. Barnhill D, Heller P, Brzozowski P, Advani H, Gallup D, Park R. Epithelial ovarian carcinoma of low malignant potential. Obstet Gynecol 1985; 65: 53-9.
18. Piura B, Dgani R, Blickstein I, Yanai-Inbar I, Czernobilsky B, Glezerman M. Epithelial ovarian tumors of borderline malignancy: a study of 50 cases. Int J Gynecol Cancer 1992; 2: 189-97.
19. Guerrieri C, Högberg T, Wingren S, Fristedt S, Simonsen E, Boeryd B. Mucinous borderline and malignant tumors of the ovary. Cancer 1994; 74: 2329-40.
20. Elchalal U, Dgani R, Piura B, Anteby SO, Zalet Y, Czernobilsky B, Schenker JG. Current concepts in management of epithelial ovarian tumors of low malignant potentials. Obstet Gynecol Surv 1995, 50: 62-70.
21. Tazelaar HD, Botswick DG, Ballon SC, Hendrickson MR, Kempson RL. Conservative treatment of borderline ovarian tumors. Obstet Gynecol 1985; 66: 417-22.
22. Bell DA, Weinstock MA, Scully RE. Peritoneal implants of ovarian serous borderline tumors. Cancer 1988; 62: 2212-22.
23. Gershenson DM, Silva EG. Serous ovarian tumors of low malignant potential with peritoneal implants. Cancer 1990; 65: 578-85.
24. Fort MG, Pierce VK, Saigo PE, Hoskins WJ, Lewis JL. Evidence for the efficacy of adjuvant therapy in epithelial ovarian tumors of low malignant potential. Gynecol Oncol 1989; 32: 269-72.
25. Aure JC, Hoeg K, Kolstad P. Clinical and histologic studies of ovarian carcinoma: long-term follow-up of 990 cases. Obstet Gynecol 1971; 37: 1-9.
26. Kühn W, Kaufman M, Feichter CE, et al. DNA flow cytometry, clinical and morphological parameters as prognostic factors for advanced malignant and borderline ovarian tumors. Gynecol Oncol 1989; 33: 360-9.
27. Friedlander ML, Russel P, Taylor IW, Hedley DW, Tattersall MHN. Flow cytometric analysis of cellular DNA content as an adjuvant to the diagnosis of ovarian tumors of borderline malignancy. Pathology 1984; 16: 301-6.
28. Harlow BL, Fuhr JE, McDonald TW, Schwartz SM, Beuerlein FJ, Weiss NS. Flow cytometry as a prognostic indicator in women with borderline epithelial ovarian tumors. Gynecol Oncol 1993; 50: 305-9.